| 02.20.25 | Pharma leaders gear up for Trump meeting; CDC puts kibosh on flu shot campaign: report

Klicken Sie hier, um Fiercebiotech.com zu abonnieren

Laden...

Gestern um 20:42

Html
Text

PM Tracker

Webinar: AI Сloud for Life Sciences. New Single Cell Foundational Model Use Case

Wednesday, February 26, 2025 | 12pm ET / 9am PT

In today’s world, life sciences and healthcare companies face major challenges — managing complex datasets, accelerating drug discovery, and advancing precision research. Register for our webinar to learn how to overcome these challenges using AI cloud infrastructure and advanced machine learning tools.

Today’s Big News

Feb 20, 2025

PhRMA leaders prepare to meet with Trump as new chair Albert Bourla espouses optimism

CDC’s ‘Wild to Mild’ flu vaccine campaign muzzled amid HHS handover: report

Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs

Merck, plaintiff agree to hit the brakes on Gardasil trial in California

Illumina maps out entry into spatial transcriptomics

Canada locks down an initial 500K doses of GSK's bird flu vaccine

Webinar: Advancing ADC development: Harnessing spatial biology and AI to develop targeted therapeutic strategies

Wednesday, February 26, 2025 | 11am ET / 8am PT

Discover how the convergence of spatial biology, AI, and computational tools is transforming cancer research. This webinar explores high-multiplex spatial analysis, tumor heterogeneity, and advances in precision medicine, reshaping drug development. Register now to learn how these innovations are driving breakthroughs in oncology.

Featured

PhRMA leaders prepare to meet with Trump as new chair Albert Bourla espouses optimism

By Fraiser Kansteiner

Ahead of a meeting with President Donald Trump, trade group the Pharmaceutical Research and Manufacturers of America is welcoming its new board chair and drafting plans for government-industry collaboration in the coming months.

CDC’s ‘Wild to Mild’ flu vaccine campaign muzzled amid HHS handover: report

By Andrea Park

A popular awareness campaign now in its second year that encouraged people to get flu vaccines to reduce their risk of severe infection has been halted at the CDC, NPR reports.

Incyte pens $885M biobucks AI pact to use Genesis' GEMS to develop new drugs

By James Waldron

Incyte is sticking to its strategy this year of finding “early-stage, exotic stuff”—paying Genesis Therapeutics $30 million upfront to use the biotech’s artificial intelligence platform to develop small-molecule medicines against undisclosed targets

Merck, plaintiff agree to hit the brakes on Gardasil trial in California

By Zoey Becker

Attorneys on the plaintiff's side, who are arguing that the vaccine caused injuries, proposed a restart in September with a new jury.

Webinar: Glycoproteomic biomarkers in the clinic: How InterVenn is powering the development of predictive biomarkers for therapeutic response

Thursday, February 27, 2025 | 2pm ET / 11am PT

The quest to discover biomarkers for therapeutic response through traditional genomic sequencing and other omic approaches has yet to deliver clinically actionable tools for most patients. Don’t miss this compelling discussion on how cutting-edge glycoproteomic technologies are unlocking new clinical insights.

Illumina maps out entry into spatial transcriptomics

By Conor Hale

The company said its spatial technology will run on its current NextSeq and NovaSeq hardware through a new multimodal software platform, with a full commercial release scheduled for 2026.

Canada locks down an initial 500K doses of GSK's bird flu vaccine

By Fraiser Kansteiner

The Public Health Agency of Canada has leveraged an existing deal with GSK to lock down an initial supply of 500,000 doses of the British drugmaker’s avian influenza vaccine for humans. Overall, 60% of available doses will be shipped out, with Canada holding back another 40% in a federal stockpile.

US biotech Hookipa retracts merger plans with UK company

By Gabrielle Masson

After announcing acquisition plans at the beginning of 2025, immunotherapeutics biotech Hookipa Pharma has decided not to buy rare disease company Poolbeg Pharma.

AstraZeneca pays $160M for FibroGen's China unit, regional rights to roxadustat

By James Waldron

AstraZeneca is paying $160 million for FibroGen’s Chinese business, giving the U.K.-based Big Pharma the regional rights to oral anemia drug roxadustat.

German research institute teams up with Barbados to improve cardiometabolic treatments for Black individuals

By Gabrielle Masson

BioMed X Institute is teaming up with the Barbados government in an effort to accelerate cardiometabolic treatments for people of African descent.

Heart monitoring patch maker VitalConnect raises $100M

By Conor Hale

The wearable cardiac monitor maker VitalConnect has raised $100 million to help develop its in-hospital wireless patient trackers.

Fierce podcasts

Don’t miss an episode

A heartwarming review of cardiovascular news, most-loved stories

This week on "The Top Line," we celebrate Valentine's Day with a discussion about heart-related updates and the stories we've loved covering so far this year.

Looking ahead at the most anticipated drug launches of 2025

How do certified community behavioral health clinics work?

Webinar: Pharmacy Considerations for Early Phase Trials

Tuesday, March 4, 2025 | 2pm ET / 11am PT

Learn expert strategies for overcoming the unique challenges of early phase clinical trials, from preparing investigational products to maintaining blinding and sourcing controlled substances. This webinar provides actionable insights to optimize pharmacy activities and ensure trial success. Register now.